Research ArticleOriginal Article

Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer

Cuicui Zhang, Jing Wang, Xinyue Wang, Zhaoting Meng, Ying Cheng and Kai Li
Cancer Biology & Medicine August 2022, 19 (8) 1249-1258; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0727

References

  1. 1.↵
    2. Ramaswamy G,
    3. Page N,
    4. Morgensztern D,
    5. Read W,
    6. Tierney R,
    7. Vlahiotis A, et al.
    Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006; 24: 4539–44.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    2. Puglisi M,
    3. Dolly S,
    4. Faria A,
    5. Myerson JS,
    6. Popat S,
    7. O’Brien ME.
    Treatment options for small cell lung cancer-do we have more choice? Br J Cancer. 2010; 102: 629–38.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    2. Sun YK,
    3. Niu W,
    4. Du F,
    5. Du CX,
    6. Li ST,
    7. Wang JW, et al.
    Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016; 9: 105.
    OpenUrl
  4. 4.↵
    2. Xie C,
    3. Wan X,
    4. Quan H,
    5. Zheng M,
    6. Fu L,
    7. Li Y, et al.
    Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018; 109: 1207–19.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. Han BH,
    3. Li K,
    4. Wang QM,
    5. Zhang L,
    6. Shi JH,
    7. Wang ZH, et al.
    Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer. JAMA Oncology. 2018; 4: 1569–75.
    OpenUrl
  6. 6.↵
    2. Cheng Y,
    3. Wang QM,
    4. Li K,
    5. Shi JH,
    6. Liu Y,
    7. Wu L, et al.
    Anlotinib as third-or further-line treatment for patients with small-cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase 2 study. Br J Cancer. 2021; doi: 10.1038/s41416-021-01356-3.
    OpenUrlCrossRef
  7. 7.↵
    2. Stemmer SM,
    3. Manojlovic NS,
    4. Marinca MV,
    5. Petrov P,
    6. Cherciu N,
    7. Ganea D, et al.
    Namodenoson in advanced hepatocellular carcinoma and child-pugh B cirrhosis: randomized placebo-controlled clinical trial. Cancers (Basel). 2021; 13: 187.
    OpenUrl
  8. 8.↵
    2. Huang WH,
    3. Wang SG,
    4. Zhang H,
    5. Zhang B,
    6. Wang CL.
    Prognostic significance of combined fibrinogen concentration and neutrophil-to-lymphocyte ratio in patients with resectable non-small cell lung cancer. Cancer Biol Med. 2018; 15: 88–96.
    OpenUrlAbstract/FREE Full Text
  9. 9.
    2. Zhang SN,
    3. Li MJ,
    4. Yuan FF,
    5. Chen L,
    6. Mi RH,
    7. Wei XD, et al.
    The predictive value of dynamic monitoring of peripheral blood lymphocyte to monocyte ratio in patients with extranodal NK/T cell lymphoma. Cancer Cell Int. 2019; 19: 272.
    OpenUrl
  10. 10.
    2. Yang C,
    3. Luo XJ,
    4. Fan L,
    5. Sha W,
    6. Xiao HP,
    7. Cui HY.
    Performance of interferon-gamma release assays in the diagnosis of nontuberculous mycobacterial diseases – a retrospective survey from 2011 to 2019. Front Cell Infect Microbiol. 2021; 10: 571230.
  11. 11.
    2. Qiu L,
    3. Jin X,
    4. Wang JJ,
    5. Tang XD,
    6. Fang X,
    7. Li SJ, et al.
    Plasma neutrophil-to-lymphocyte ratio on the third day postburn is associated with 90-day mortality among patients with burns over 30% of total body surface area in two Chinese burns centers. J Inflamm Res. 2021; 14: 519–26.
    OpenUrl
  12. 12.↵
    2. Wang J,
    3. Zhao YZ,
    4. Wang QM,
    5. Zhang L,
    6. Shi JH,
    7. Wang ZH, et al.
    Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment. Cancer Biol Med. 2018; 15: 443–51.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    2. Sun JM,
    3. Choi YL,
    4. Ji JH,
    5. Ahn JS,
    6. Kim KM,
    7. Han J, et al.
    Small cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing. Ann Oncol. 2015; 26: 161–6.
    OpenUrlCrossRefPubMed
  14. 14.↵
    2. Han JY,
    3. Kim HY,
    4. Lim KY,
    5. Han JH,
    6. Lee YJ,
    7. Kwak MH, et al.
    A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer. 2013; 79: 137–42.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    2. Allen JW,
    3. Moon J,
    4. Redman M,
    5. Gadgeel SM,
    6. Kelly K,
    7. Mack PC, et al.
    Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol. 2014; 32: 2463–70.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    2. Cedrés S,
    3. Torrejon D,
    4. Martínez A,
    5. Martinez P,
    6. Navarro A,
    7. Zamora E, et al.
    Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012; 14: 864–9.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Kasuga I,
    3. Makino S,
    4. Kiyokawa H,
    5. Katoh H,
    6. Ebihara Y,
    7. Ohyashiki K.
    Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer. 2001; 92: 2399–405.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    2. Hald SM,
    3. Bremnes RM,
    4. Al-Shibli K,
    5. Al-Saad S,
    6. Andersen S,
    7. Stenvold H, et al.
    CD4/CD8 co-expression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy. Lung Cancer. 2013; 80: 209–15.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Fukumura D,
    3. Kloepper J,
    4. Amoozgar Z,
    5. Duda DG,
    6. Jain RK.
    Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15: 325–40.
    OpenUrlCrossRefPubMed
  20. 20.↵
    2. Li B,
    3. Lalani AS,
    4. Harding TC,
    5. Luan B,
    6. Koprivnikar K,
    7. Tu GH, et al.
    Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res. 2006; 12: 6808–16.
    OpenUrlAbstract/FREE Full Text
  21. 21.
    2. Motz GT,
    3. Coukos G.
    The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol. 2011; 11: 702–11.
    OpenUrlCrossRefPubMed
  22. 22.↵
    2. Fricke I,
    3. Mirza N,
    4. Dupont J,
    5. Lockhart C,
    6. Jackson A,
    7. Lee J-H, et al.
    Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res. 2007; 13: 4840–8.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    2. Liu SC,
    3. Qin TT,
    4. Liu ZJ,
    5. Wang J,
    6. Jia YN,
    7. Feng YF, et al.
    Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 2020; 11: 309.
    OpenUrl
  24. 24.↵
    2. Chu TQ,
    3. Zhong RB,
    4. Zhong H,
    5. Zhang B,
    6. Zhang W,
    7. Shi C, et al.
    Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. J Thorac Oncol. 2021; 16: 643–52.
    OpenUrlPubMed
  25. 25.↵
    2. Hofbauer SL,
    3. Stangl KI,
    4. de Martino M,
    5. Lucca I,
    6. Haitel A,
    7. Shariat SF, et al.
    Pretherapeutic gamma-glutamyl transferase is an independent prognostic factor for patients with renal cell carcinoma. Br J Cancer. 2014; 111: 1526–31.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Corti A,
    3. Franzini M,
    4. Paolicchi A,
    5. Pompella A.
    Gamma-glutamyl transferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res. 2010; 30: 1169–81.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    2. Diem S,
    3. Kasenda B,
    4. Spain L,
    5. Martin-Liberal J,
    6. Marconcini R,
    7. Gore M.
    Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer. 2016; 114: 256–61.
    OpenUrlCrossRefPubMed
  28. 28.↵
    2. Zhang LX,
    3. Lv Y,
    4. Xu AM,
    5. Wang HZ.
    The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma. BMC Cancer. 2019; 19: 841.
    OpenUrl
  29. 29.↵
    2. Fan SS,
    3. Guan Y,
    4. Zhao GF,
    5. An GY.
    Association between plasma fibrinogen and survival in patients with small-cell lung carcinoma. Thorac Cancer. 2018; 9: 146–51.
    OpenUrl
  30. 30.↵
    2. Tas F,
    3. Kilic L,
    4. Serilmez M,
    5. Keskin S,
    6. Sen F,
    7. Duranyildiz D.
    Clinical and prognostic significance of coagulation assays in lung cancer. Respir Med. 2013; 107: 451–7.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords